Abbott announced...that it has entered into an agreement with Pfizer Inc to develop a molecular diagnostic test intended to screen non-small cell lung cancer...tumors for the presence of gene rearrangements. Pfizer has developed a novel investigational agent that selectively targets cancer-causing genes implicated in the progress of many cancers. To be eligible to receive Pfizer's oral therapy, a particular genetic translocation (rearrangement) known to be found in NSCLC [non-small cell lung cancer] tumors and a wide variety of other cancers, but not in normal cells, must be present. Under terms of the agreement, Abbott will develop a companion diagnostic test that will determine a patient's genetic status and will be used in patient selection for future clinical trials of PF-02341066.
...[D]uring lean economic times, Pfizer may have decided to work with Abbott, searching for a diagnostics partner that would require less investment than a smaller company. Historically, Pfizer has worked with comparatively smaller diagnostic shops, such as Monogram Biosciences and Genomic Health to develop tests for its pharmacogenomically guided drugs. In doing so, Pfizer has made significant investments in the companies, shouldering the brunt of the development and marketing costs.